Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCH-IV Treatment Protocol for Pediatric Langerhans Cell Histiocytosis
NCT02205762Phase 3Active, not recruiting
- Sponsor
- North American Consortium for Histiocytosis
- Start
- Nov 2016
- Primary completion
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of vinblastine, prednisone, mercaptopurine, cytarabine, cladribine in Langerhans cell histiocytosis (LCH), sponsored by North American Consortium for Histiocytosis. Started Nov 2016; status: active, not recruiting.
02
Drugs
vinblastineprednisonemercaptopurinecytarabinecladribine
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on NCT02205762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02205762.